Eastern Cooperative Oncology Group
265
5
13
211
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
13.6%
36 terminated/withdrawn out of 265 trials
85.4%
-1.2% vs industry average
39%
104 trials in Phase 3/4
34%
71 of 211 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (265)
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Role: collaborator
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Role: lead
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
Role: lead
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
Role: lead
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Role: lead
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Role: lead
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Role: collaborator
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Role: collaborator
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Role: collaborator
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Role: lead
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Role: collaborator
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Role: collaborator
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Role: collaborator
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Role: lead
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
Role: collaborator
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Role: lead
A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)
Role: lead
SMART-ER: Symptom Monitoring With Patient-reported Outcomes
Role: collaborator
Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol
Role: lead
Tomosynthesis Mammographic Imaging Screening Trial
Role: collaborator